Compared to patients with autoimmune disorders and no anti-TNFα use, there were no significant associations between anti-TNFα therapy and tinnitus when restricting the Yes-TNFα population to those with ≥6 (hdPS-adjusted HR [95% CI]: 0.96 [0.69, 1.32]) or ≥12 months (1.03 [0.71, 1.50]) of anti-TNFα (Figure S3), or to only patients with RA (1.16 [0.88, 1.53]) (Figure S4). This evidence concerns the gene TNF and autoimmune disease.